Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Charles River Laboratories International, Inc. has reported a financial loss and confirmed that it has laid off dozens of employees, specifically 36 workers. This decision is part of a broader effort to streamline operations and improve financial performance. The company is optimistic about its turnaround strategy, indicating that it remains on track despite the recent job cuts. The layoffs reflect ongoing challenges within the organization as it seeks to stabilize its operations and enhance profitability.
Charles River Laboratories International, Inc. has announced the closure of a 20,000-square-foot facility, resulting in the layoff of 20 employees. This decision reflects the company's ongoing adjustments in response to market conditions. The layoffs are part of a broader strategy to streamline operations and focus on core business areas. Specific details regarding the location of the facility or the departments affected were not disclosed in the article.
Charles River Laboratories International, Inc. is planning significant workforce reductions as part of a strategy to cut costs in response to a continuing decline in revenue. The company has indicated that these layoffs are part of a broader shift in direction aimed at stabilizing its financial performance. Specific details regarding the number of employees affected or the timeline for these layoffs have not been disclosed. This decision reflects the company's ongoing challenges in the current market environment.
Charles River Laboratories International, Inc. has announced plans to lay off up to 31 employees at its pathology site in North Carolina. This decision comes as the company prepares to shutter the facility, indicating a significant operational shift. The layoffs are part of a broader restructuring strategy aimed at optimizing the company's resources and capabilities. While the exact date for these layoffs has not been specified, the company is moving forward with its plans to discontinue operations at this location. The affected department is pathology, which has been a key area for the company.
Charles River Laboratories International, Inc., a life sciences company based in Massachusetts, has announced plans to lay off dozens of workers in 2026. The specific number of employees affected is estimated to be around 36. While the article does not provide detailed information about the reasons for the layoffs or the departments involved, it highlights the company's intention to reduce its workforce in the upcoming year. This decision reflects ongoing adjustments within the company as it navigates the evolving landscape of the life sciences industry.
Charles River Laboratories International, Inc. has laid off approximately 70 employees as part of a strategic relocation initiative. This decision marks the beginning of a shift in the company's operational strategy. The layoffs are part of a broader effort to streamline operations and enhance efficiency. While specific details regarding the location or departments affected were not disclosed, this move reflects the company's ongoing adjustments in response to market conditions. The layoffs have already taken place, indicating a decisive step in the company's restructuring efforts.
Charles River Laboratories International, Inc. has announced a total of 170 layoffs affecting its operations in Littleton and Tewksbury, Massachusetts. The layoffs are part of a broader restructuring effort aimed at streamlining operations and improving efficiency. The company has not specified the exact departments impacted by these layoffs. This decision reflects ongoing challenges within the industry and the need for companies to adapt to changing market conditions. The layoffs are effective immediately as part of the company's efforts to realign its workforce with current business needs.
Charles River Laboratories International, Inc. has laid off approximately 200 employees as part of a strategic review aimed at improving operational efficiency. The layoffs occurred in Wilmington, Massachusetts, and are part of the company's ongoing efforts to streamline its operations. This decision reflects the company's response to current market conditions and aims to position it for future growth. The layoffs are part of a broader restructuring initiative that the company has been implementing to enhance its competitiveness in the industry.
Charles River Laboratories International, Inc. has announced a significant reduction in its workforce, cutting 25% of its employees in Cambridge, which translates to approximately 250 layoffs. This decision comes as part of a broader restructuring effort aimed at streamlining operations and improving efficiency. The company has indicated that these layoffs are necessary to adapt to changing market conditions and to focus on its core business areas. The layoffs are expected to impact various roles within the organization, although specific departments affected have not been detailed. This move reflects ongoing challenges in the biotech sector, where many companies are reevaluating their workforce in response to economic pressures.
Charles River Laboratories International, Inc. has laid off approximately 300 employees as part of a strategic review aimed at improving operational efficiency. The layoffs occurred at their Wilmington, Massachusetts location and are part of ongoing efforts to streamline the company's operations. This decision reflects the company's response to current market conditions and aims to align resources more effectively. The layoffs are part of a broader trend in the industry as companies adjust to changing demands and economic pressures.
Charles River Laboratories International, Inc. has laid off 150 employees at its Cambridge facility as part of a winding down process. This decision reflects the company's strategic adjustments and operational changes in response to market conditions. The layoffs are part of a broader trend affecting the biotech industry, but specific reasons for this reduction were not detailed. The company continues to assess its workforce needs as it navigates through these challenging times.
Charles River Laboratories International, Inc. has laid off approximately 100 employees at its cell therapy manufacturing site in Memphis, Tennessee. The layoffs were part of a restructuring effort aimed at streamlining operations and improving efficiency. This decision comes as the company seeks to adapt to changing market conditions and optimize its workforce. The affected employees were primarily involved in the production of cell therapy products, which have seen fluctuating demand. The company has not specified any future layoffs but is focusing on enhancing its operational capabilities.
No one has shared a story from Charles River Laboratories Inte yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.